Is JANX or JAZZ more undervalued in 2026?

CirclFi compares Janux Therapeutics, Inc. (JANX) and Jazz Pharmaceuticals plc (JAZZ) using 13 institutional-grade valuation models. JANX has a Quality of Company score of 5.4/10 while JAZZ scores 7.5/10.

Which is a better buy — JANX or JAZZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do JANX and JAZZ valuations compare?

JANX at $14.74 and JAZZ at $235.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

JANX vs JAZZ Valuation Comparison 2026 — Intrinsic Value Analysis

JANX

Biotechnology

Janux Therapeutics, Inc.

Quality

5.4

out of 10

Value Trap

SAFE

Price

$14.74

Last close

Models

9/13

Active

JAZZ

Biotechnology

Jazz Pharmaceuticals plc

Quality

7.5

out of 10

Value Trap

SAFE

Price

$235.38

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	JANX Fair Value	JANX Upside	JAZZ Fair Value	JAZZ Upside
Bayesian DCF	Intrinsic	$4.28	-71.0%	$399.99	+69.9%
EROIC Spread	Intrinsic	—	—	$108.93	-44.6%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$9.03	-38.7%	$27.12	-88.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for JANX vs JAZZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

JANX vs JAZZ — Which Stock Is More Undervalued?

JAZZ scores higher with a 7.5/10 quality rating vs JANX's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Janux Therapeutics, Inc. (JANX) and Jazz Pharmaceuticals plc (JAZZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

JANX currently trades at $14.74 with a QOC of 5.4/10, while JAZZ trades at $235.38 with a QOC of 7.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).